Elafibranor

Description: Elafibranor (formerly GFT505) is a dual agonist of the PPARalpha/delta (peroxisome proliferator-activated receptor-alpha and -delta) with EC50 values of 45 and 175 nM, respectively. It can improve insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. Currently elafibranor is being developed for the treatment of T2DM and non-alcoholic fatty liver disease as well as cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD). Elafibranor has an active metabolite, GFT1007, and both have potent agonist activity for PPAR-alpha and to a lesser extent for PPAR-delta.

References: Expert Opin Investig Drugs. 2015 May; 24(5):611-21; Gastroenterology. 2016 May; 150(5):1147-1159.e5.

GFT-505; GFT505; Elafibranor; GFT 505;